RU2010119458A - 1,3,5-тризамещенное производное триазола - Google Patents
1,3,5-тризамещенное производное триазола Download PDFInfo
- Publication number
- RU2010119458A RU2010119458A RU2010119458/04A RU2010119458A RU2010119458A RU 2010119458 A RU2010119458 A RU 2010119458A RU 2010119458/04 A RU2010119458/04 A RU 2010119458/04A RU 2010119458 A RU2010119458 A RU 2010119458A RU 2010119458 A RU2010119458 A RU 2010119458A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- compound
- pharmaceutically acceptable
- nicotinic receptor
- diseases
- Prior art date
Links
- -1 1,3,5-TRI-SUBSTITUTED TRIAZOLE Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims abstract 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims abstract 4
- 230000009286 beneficial effect Effects 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 229940122656 Alpha-7 nicotinic receptor agonist Drugs 0.000 claims abstract 2
- 239000007818 Grignard reagent Substances 0.000 claims abstract 2
- 201000006347 Intellectual Disability Diseases 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 230000003197 catalytic effect Effects 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000004795 grignard reagents Chemical class 0.000 claims abstract 2
- 239000008240 homogeneous mixture Substances 0.000 claims abstract 2
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 2
- AQBLLJNPHDIAPN-LNTINUHCSA-K iron(3+);(z)-4-oxopent-2-en-2-olate Chemical compound [Fe+3].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O AQBLLJNPHDIAPN-LNTINUHCSA-K 0.000 claims abstract 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 208000020016 psychiatric disease Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000002904 solvent Substances 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Соединение формулы (I) !! или его фармацевтически приемлемая соль, или гидрат, или сольват. ! 2. Применение соединения для производства лекарственного средства для предотвращения или лечения, или профилактики психических расстройств, расстройств или заболеваний нарушения интеллекта, воспалительных заболеваний или состояний, при которых является благоприятной модуляция α7 никотинового рецептора, где соединение является соединением по п.1. ! 3. Фармацевтическая композиция, содержащая фармацевтически приемлемый носитель и, в качестве активного компонента терапевтически эффективное количество соединения по п.1. ! 4. Способ получения композиции по п.3, отличающийся тем, что фармацевтически приемлемый носитель смешивается до получения однородной смеси с терапевтически эффективным количеством соединения по п.1. ! 5. Продукт, содержащий ! (a) соединение по п.1 и ! (b) агонист α7 никотинового рецептора в качестве комбинированного препарата для одновременного, раздельного или последовательного применения при предотвращении или лечении заболеваний, при которых является благоприятной модуляция α7 никотинового рецептора. ! 6. Способ получения соединения по п.1, включающий стадию взаимодействия промежуточного соединения формулы (VI) с избытком реактива Гриньяра MeMgBr ! ! в присутствии каталитических количеств ацетилацетоната железа(III) в системе растворителей, состоящей из 75-85% ТГФ и 15-25% NМP по объему, в диапазоне температур от 0°C до 50°C.
Claims (6)
1. Соединение формулы (I)
или его фармацевтически приемлемая соль, или гидрат, или сольват.
2. Применение соединения для производства лекарственного средства для предотвращения или лечения, или профилактики психических расстройств, расстройств или заболеваний нарушения интеллекта, воспалительных заболеваний или состояний, при которых является благоприятной модуляция α7 никотинового рецептора, где соединение является соединением по п.1.
3. Фармацевтическая композиция, содержащая фармацевтически приемлемый носитель и, в качестве активного компонента терапевтически эффективное количество соединения по п.1.
4. Способ получения композиции по п.3, отличающийся тем, что фармацевтически приемлемый носитель смешивается до получения однородной смеси с терапевтически эффективным количеством соединения по п.1.
5. Продукт, содержащий
(a) соединение по п.1 и
(b) агонист α7 никотинового рецептора в качестве комбинированного препарата для одновременного, раздельного или последовательного применения при предотвращении или лечении заболеваний, при которых является благоприятной модуляция α7 никотинового рецептора.
6. Способ получения соединения по п.1, включающий стадию взаимодействия промежуточного соединения формулы (VI) с избытком реактива Гриньяра MeMgBr
в присутствии каталитических количеств ацетилацетоната железа(III) в системе растворителей, состоящей из 75-85% ТГФ и 15-25% NМP по объему, в диапазоне температур от 0°C до 50°C.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118822 | 2007-10-18 | ||
| EP07118822.1 | 2007-10-18 | ||
| PCT/EP2008/063844 WO2009050185A1 (en) | 2007-10-18 | 2008-10-15 | 1,3,5-trisubstituted triazole derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010119458A true RU2010119458A (ru) | 2011-11-27 |
| RU2476433C2 RU2476433C2 (ru) | 2013-02-27 |
Family
ID=39047591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010119458/04A RU2476433C2 (ru) | 2007-10-18 | 2008-10-15 | 1,3,5-тризамещенное производное триазола |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8404851B2 (ru) |
| EP (1) | EP2205594B1 (ru) |
| JP (1) | JP2011500624A (ru) |
| CN (1) | CN101827839B (ru) |
| AR (1) | AR068919A1 (ru) |
| AT (1) | ATE522523T1 (ru) |
| AU (1) | AU2008313775B2 (ru) |
| CA (1) | CA2697982C (ru) |
| CL (1) | CL2008003067A1 (ru) |
| ES (1) | ES2371863T3 (ru) |
| IL (1) | IL205102A (ru) |
| JO (1) | JO2784B1 (ru) |
| MX (1) | MX2010004176A (ru) |
| PA (1) | PA8799901A1 (ru) |
| PE (1) | PE20091080A1 (ru) |
| RU (1) | RU2476433C2 (ru) |
| TW (1) | TW200934491A (ru) |
| WO (1) | WO2009050185A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20115241B (en) * | 2006-10-19 | 2011-06-10 | Takeda Pharmaceutical | Indole compound |
| ES2424023T3 (es) * | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-triazoles trisustituidos |
| AU2009226988B2 (en) * | 2008-03-19 | 2013-05-23 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
| BRPI0912196A2 (pt) * | 2008-05-09 | 2015-10-06 | Janssen Pharmaceutica Nv | pirazóis trissubstituídos como moduladores do receptor de acetilcolina. |
| CA2825519A1 (en) | 2011-02-03 | 2012-09-08 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
| CA2826792A1 (en) | 2011-02-23 | 2012-08-30 | Lupin Limited | Heteroaryl derivatives as alpha7 nachr modulators |
| EP2678315B1 (en) | 2011-02-25 | 2015-12-16 | Janssen Pharmaceutica, N.V. | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR |
| EP2691368A1 (en) | 2011-03-31 | 2014-02-05 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| US8946432B2 (en) | 2011-07-05 | 2015-02-03 | Lupin Limited | Biaryl derivatives as nAChR modulators |
| US9388196B2 (en) | 2012-03-06 | 2016-07-12 | Lupin Limited | Thiazole derivatives as alpha 7 nAChR modulators |
| WO2014072957A1 (en) | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| EP2945941B1 (en) | 2013-01-16 | 2016-12-07 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| EP2970180A1 (en) | 2013-03-13 | 2016-01-20 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| US9504680B2 (en) | 2013-06-17 | 2016-11-29 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795907A (fr) * | 1972-02-25 | 1973-06-18 | Luso Farmaco Inst | 2-amino-4-arylthiazoles 5-substitues et leur preparation |
| EP0248523B1 (en) | 1986-05-07 | 1991-10-16 | FISONS plc | Pyrazoles |
| JPS6339868A (ja) | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
| US4761422A (en) | 1986-11-20 | 1988-08-02 | Lusofarmaco Istituto Lusofarmaco D'italia Spa | (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same |
| WO1996003392A1 (en) | 1994-07-27 | 1996-02-08 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
| KR970705560A (ko) | 1995-08-02 | 1997-10-09 | 호아껭 우리아치 토렐로 | 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity) |
| FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
| ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| CA2302417A1 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
| FR2792314B1 (fr) | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
| WO2001010865A1 (fr) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE p38MAP KINASE |
| FR2802530B1 (fr) | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| WO2001064674A1 (en) | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
| US6586453B2 (en) | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
| US6515005B2 (en) | 2000-09-21 | 2003-02-04 | Bristol-Myers Squibb Company | Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| CA2432870A1 (en) | 2000-12-22 | 2002-07-25 | Ronghui Lin | Substituted triazole diamine derivatives as kinase inhibitors |
| HUP0401748A3 (en) | 2001-08-13 | 2011-03-28 | Janssen Pharmaceutica Nv | 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them |
| EP1441732A2 (en) * | 2001-11-08 | 2004-08-04 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivative and pharmaceutical use thereof |
| CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| CN1561340B (zh) * | 2002-01-28 | 2012-05-23 | 株式会社富士药品 | 1,2,4-三唑类化合物 |
| US7300933B2 (en) * | 2002-05-07 | 2007-11-27 | Neurosearch A/S | Diazabicyclic biaryl derivatives |
| WO2004013120A1 (en) * | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| US20070191267A1 (en) | 2003-04-28 | 2007-08-16 | Ab Science | Use of tyrosine kinase inhibitors for treating cerebral ischemia |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| PT1635824E (pt) * | 2003-06-03 | 2009-11-24 | Novartis Ag | Inibidores de p-38 à base de heterociclos de 5 membros |
| US20090018150A1 (en) | 2003-07-24 | 2009-01-15 | Asterand Uk Limited | 5-Ht2b Receptor Antagonists |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| CN1942450A (zh) * | 2004-02-11 | 2007-04-04 | 詹森药业有限公司 | 取代三唑化合物的制备方法 |
| ZA200702645B (en) * | 2004-09-17 | 2008-08-27 | Vertex Pharma | Diaminotriazole compounds useful as protein kinase inhibitors |
| DK1811998T3 (da) | 2004-10-21 | 2011-02-14 | Vertex Pharma | Triazoler anvendelige som inhibitorer af proteinkinaser |
| WO2006064375A2 (en) | 2004-12-16 | 2006-06-22 | Ab Science | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases |
| MX2007008434A (es) * | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
| CN101263130B (zh) * | 2005-09-13 | 2011-03-09 | 詹森药业有限公司 | 2-苯胺-4-芳基取代的噻唑衍生物 |
| JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| ES2424023T3 (es) * | 2007-10-18 | 2013-09-26 | Janssen Pharmaceutica N.V. | 1,2,4-triazoles trisustituidos |
| AU2009226988B2 (en) * | 2008-03-19 | 2013-05-23 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
| WO2009127678A1 (en) | 2008-04-17 | 2009-10-22 | Glaxo Group Limited | Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71 |
| BRPI0912196A2 (pt) * | 2008-05-09 | 2015-10-06 | Janssen Pharmaceutica Nv | pirazóis trissubstituídos como moduladores do receptor de acetilcolina. |
| KR101710197B1 (ko) * | 2009-09-17 | 2017-02-24 | 얀센 파마슈티카 엔.브이. | 치환된 ｎ-페닐-1-(4-피리디닐)-1ｈ-피라졸-3-아민 |
| JO3078B1 (ar) * | 2009-11-27 | 2017-03-15 | Janssen Pharmaceutica Nv | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة |
| EP2678315B1 (en) | 2011-02-25 | 2015-12-16 | Janssen Pharmaceutica, N.V. | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR |
-
2008
- 2008-09-15 JO JO2008412A patent/JO2784B1/en active
- 2008-10-15 EP EP08805280A patent/EP2205594B1/en active Active
- 2008-10-15 JP JP2010529360A patent/JP2011500624A/ja active Pending
- 2008-10-15 AU AU2008313775A patent/AU2008313775B2/en not_active Ceased
- 2008-10-15 CN CN2008801119538A patent/CN101827839B/zh not_active Expired - Fee Related
- 2008-10-15 ES ES08805280T patent/ES2371863T3/es active Active
- 2008-10-15 US US12/738,725 patent/US8404851B2/en active Active
- 2008-10-15 MX MX2010004176A patent/MX2010004176A/es active IP Right Grant
- 2008-10-15 AT AT08805280T patent/ATE522523T1/de not_active IP Right Cessation
- 2008-10-15 RU RU2010119458/04A patent/RU2476433C2/ru active
- 2008-10-15 WO PCT/EP2008/063844 patent/WO2009050185A1/en active Application Filing
- 2008-10-15 CA CA2697982A patent/CA2697982C/en active Active
- 2008-10-16 CL CL2008003067A patent/CL2008003067A1/es unknown
- 2008-10-17 PA PA20088799901A patent/PA8799901A1/es unknown
- 2008-10-17 PE PE2008001789A patent/PE20091080A1/es active IP Right Grant
- 2008-10-17 TW TW097139807A patent/TW200934491A/zh unknown
- 2008-10-17 AR ARP080104545A patent/AR068919A1/es not_active Application Discontinuation
-
2010
- 2010-04-15 IL IL205102A patent/IL205102A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AR068919A1 (es) | 2009-12-16 |
| CA2697982C (en) | 2015-09-22 |
| ES2371863T3 (es) | 2012-01-10 |
| RU2476433C2 (ru) | 2013-02-27 |
| EP2205594A1 (en) | 2010-07-14 |
| US8404851B2 (en) | 2013-03-26 |
| CN101827839A (zh) | 2010-09-08 |
| AU2008313775B2 (en) | 2012-12-13 |
| JO2784B1 (en) | 2014-03-15 |
| CL2008003067A1 (es) | 2009-11-27 |
| IL205102A (en) | 2015-04-30 |
| PA8799901A1 (es) | 2009-05-15 |
| CA2697982A1 (en) | 2009-04-23 |
| CN101827839B (zh) | 2012-10-24 |
| EP2205594B1 (en) | 2011-08-31 |
| ATE522523T1 (de) | 2011-09-15 |
| WO2009050185A1 (en) | 2009-04-23 |
| TW200934491A (en) | 2009-08-16 |
| AU2008313775A1 (en) | 2009-04-23 |
| JP2011500624A (ja) | 2011-01-06 |
| US20100240707A1 (en) | 2010-09-23 |
| MX2010004176A (es) | 2010-05-03 |
| PE20091080A1 (es) | 2009-08-03 |
| IL205102A0 (en) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP6434482B2 (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| KR101542812B1 (ko) | 당뇨병을 치료하기 위한 선택적인 안드로겐 수용체 모듈레이터 | |
| JP5745560B2 (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| RU2472509C2 (ru) | Способ лечения артрита | |
| EP2452680B1 (en) | Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility | |
| JP2012517446A (ja) | Ｓ１ｐ５受容体の作動薬および拮抗薬ならびにそれらの使用方法 | |
| JP2014506907A5 (ru) | ||
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| JP2014507455A5 (ru) | ||
| JP2009537498A5 (ru) | ||
| WO2007134107A3 (en) | Cold menthol receptor-1 antagonists | |
| NZ595759A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| EP3409658B1 (en) | Tetrahydronaphthalene derivative | |
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2012523395A5 (ru) | ||
| JP6039100B2 (ja) | 新規選択的アンドロゲン受容体モジュレーター | |
| JP2019529460A5 (ru) | ||
| CN106572997A (zh) | 作为选择性雄激素受体调节剂的腈衍生物 | |
| JP2015502371A5 (ru) | ||
| KR20220030219A (ko) | Ep2 안타고니스트 | |
| CN104341351A (zh) | 一种新型的二芳基硫代乙内酰脲衍生物及其应用 | |
| RU2010119459A (ru) | Тризамещенные 1,2,4-триазолы |